🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the battle against increasingly resistant strains of the bacteria, according to scientists.

A Global Health Concern

The sexually transmitted infection are escalating worldwide, with data suggesting in excess of 82 million new cases annually. Notably increased rates are observed in the African continent and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary development in the face of rising global incidence, the spread of superbugs and the very limited treatment choices at this time.”

Health officials are deeply concerned about the increase in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance found that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Clearance

One new antibiotic, also known as Nuzolvence, was approved by the US FDA in mid-December for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers anticipate that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the drugmaker GSK, was also approved in concurrent days. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a unique collaborative effort for medication research. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization represents a major breakthrough in the therapy of highly resistant gonorrhoea, which previously has been outpacing medical innovation.”

Testing Outcomes and Worldwide Availability

As per data released by a major medical journal, the new drug successfully treated over nine in ten of uncomplicated infections. This puts it on an similar efficacy with the existing first-line therapy, which combines a dual-drug approach. The study included hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Doctors directly involved have shared hope. Having a one-pill regimen like this is hailed as a "game-changer" for gonorrhoea control. This is considered vital to lessen the impact of the disease for individuals and to halt the transmission of untreatable gonorrhoea worldwide.